Related Experiment Video
Updated: Jun 26, 2026
10:29
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
[Progress in the new nonnucleoside anti-HIV reverse transcriptase inhibitor-DCK]
1Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
Yao Xue Xue Bao = Acta Pharmaceutica Sinica
|January 9, 2009
Summary
Synthetic khellactone esters, known as 3
Area of Science:
- Medicinal Chemistry
- Organic Synthesis
- Virology
Context:
- Human Immunodeficiency Virus (HIV) infection remains a significant global health challenge.
- Existing antiretroviral therapies face challenges including drug resistance and side effects.
- Novel therapeutic strategies with distinct mechanisms of action are urgently needed.
Purpose:
- To review recent advancements in the discovery and development of 3',4'-Di-O-(S)-comphanoyl-(+)-cis-khellactone (DCK) derivatives as potent anti-HIV agents.
- To explore the structural modifications and structure-activity relationships (SAR) of DCK analogs.
- To highlight the unique mechanism of action of DCK derivatives compared to current HIV treatments.
Summary:
- 3',4'-Di-O-(S)-comphanoyl-(+)-cis-khellactone (DCK) is a synthetic khellactone ester with significant anti-HIV activity.
- Various DCK analogs have been synthesized and evaluated for their inhibitory effects against HIV.
- Studies focus on structural modifications and SAR to optimize anti-HIV potency and understand the distinct mechanism of action.
Impact:
- DCK derivatives represent a promising new class of compounds for HIV treatment.
- Understanding the SAR of DCK analogs can guide the design of next-generation anti-HIV drugs.
- The distinct mechanism of DCK offers a potential strategy to overcome existing drug resistance.
Related Concept Videos
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:19Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...